Market Capitalization (Millions $) |
119,870 |
Shares
Outstanding (Millions) |
1,254 |
Employees |
18,000 |
Revenues (TTM) (Millions $) |
28,299 |
Net Income (TTM) (Millions $) |
114 |
Cash Flow (TTM) (Millions $) |
-669 |
Capital Exp. (TTM) (Millions $) |
591 |
Gilead Sciences Inc
Company Profile: Gilead Sciences, Inc.
Overview: Gilead Sciences, Inc. is a leading biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics to improve the health and quality of life for patients with life-threatening diseases around the globe. Based in Foster City, California, the company has established itself as a pioneer in the field of antiviral and anti-infective therapies, with a strong focus on areas including HIV, hepatitis, and infectious diseases.
Key Products: Gilead has an extensive portfolio of marketed products, many of which have become standard therapies in their respective categories. They include:
- Viread (tenofovir disoproxil fumarate): Used in combination with other antiretroviral agents for the treatment of HIV infection, both in the United States and internationally. - Emtriva (emtricitabine): Another key antiretroviral medication approved for use in the treatment of HIV infection in adults; a fixed-dose combination with Viread is currently under development. - AmBisome (liposomal amphotericin B): Indicated for the treatment of serious fungal infections and marketed in over 45 countries globally. Gilead collaborates with Fujisawa Healthcare, Inc. for its promotion in the U.S. - Hepsera (adefovir dipivoxil): Prescribed for chronic hepatitis B treatment, marketed in both the U.S. and certain international markets, including Europe. - Tamiflu (oseltamivir phosphate): An antiviral medication used for the prevention and treatment of influenza, marketed worldwide in collaboration with Roche. - Vistide (cidofovir): Indicated for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients, marketed in the U.S. and through a partnership with Pfizer in various countries.
Commercial Operations: Gilead operates robust U.S. and international sales teams, with marketing affiliates strategically positioned across Europe, Asia, and Australia. The company utilizes a comprehensive sales strategy involving direct engagement with healthcare providers, hospitals, and clinics to ensure broad access to its products.
Collaborative Relationships: Gilead is committed to collaboration with various partners in the pharmaceutical industry to enhance its research and development capabilities. Key collaborations include:
- Archemix Corporation: Partnership involving a license for SELEX technology to discover aptamers. - Chiron Corporation: Licensing agreement for small molecule therapeutics aimed at hepatitis C. - GlaxoSmithKline: Exclusive rights granted for Hepseras commercialization in Asia and Latin America.
Recent Developments: As of 2023, Gilead continues to expand its portfolio with ongoing research and development endeavors. The company has invested in next-generation antiviral therapies, including long-acting formulations for HIV, as well as treatments for emerging infectious diseases. Its commitment to innovation is evident in the continuous expansion and improvement of its product pipeline.
Conclusion: Gilead Sciences, Inc. remains a key player in the biopharmaceutical landscape, with a focus on advancing healthcare solutions for patients with critical health needs. Through strategic collaborations and a commitment to research, Gilead aims to sustain its leadership in antiviral therapies and address unmet medical needs in infectious diseases.
Company Address: 333 Lakeside Drive Foster City 94404 CA
Company Phone Number: 574-3000 Stock Exchange / Ticker: NASDAQ GILD
|